Cantor’s Conviction List Stocks With the Most Upside in 2013 (CREE, FRX, RFMD, SLXP, UNIS)

Photo of Jon C. Ogg
By Jon C. Ogg Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

This week Cantor Fitzgerald released its inaugural list of “Conviction” equity ideas for 2013. Far from being a copycat list that mimics every other large bulge bracket firm on the street, the firm produced an eclectic list with some very intriguing names. We dissected the list and came up with five names that, based on current pricing and target projections, had the highest projected percentage gain possibilities.

Cree Inc. (NASDAQ: CREE). Cree develops and manufactures lighting-class light emitting diode (LED) products, lighting products and semiconductor products for power and radio-frequency (RF) applications. The Cantor Fitzgerald target price is $42. The median target price from other firms is $33.88. Shares are trading at $31.86, and the $42 target represents a 24.14% increase.

Forest Laboratories Inc. (NYSE: FRX). Forest Laboratories develops, manufactures and sells branded forms of ethical drug products, primarily in the United States and Europe. The price target on the Conviction List is $48. The street consensus is $38. Trading at $37.30, it offers a potential 22.29% gain.

RF Micro Devices Inc. (NASDAQ: RFMD). The company designs, develops, manufactures and markets radio frequency (RF) components and compound semiconductor technologies, primarily in the United States and Asia. Shares are trading at $4.90, and the Cantor target is $8. The consensus target is $6. A correct call here could yield a gain of more than 60%.

Salix Pharmaceuticals Ltd. (NASDAQ: SLXP). Salix acquires, develops and markets prescription drugs and medical devices used in the treatment of various gastrointestinal diseases in the United States. With shares at $45.59, the street target for Salix is $54. The Cantor target of $60 represents almost a 39% gain.

Unilife Corp. (NASDAQ: UNIS). This one designs, develops, manufactures and commercializes injectable drug delivery systems in the United States and internationally. Here is the Cantor Fitzgerald potential home run pick. With shares trading at just $2.37, their target is $7.50. The street also likes this name and has a $6.65 consensus target. But a $7.50 handle would be an astonishing 223% gain.

It is good to remember when investing that the Wall St. price target and your price target may be two very different areas. Any time you are trading stocks, you might want to always make the old Wall St. adage “Nobody ever went broke taking a profit” part of your trading discipline.

Photo of Jon C. Ogg
About the Author Jon C. Ogg →

Jon Ogg has been a financial news analyst since 1997. Mr. Ogg set up one of the first audio squawk box services for traders called TTN, which he sold in 2003. He has previously worked as a licensed broker to some of the top U.S. and E.U. financial institutions, managed capital, and has raised private capital at the seed and venture stage. He has lived in Copenhagen, Denmark, as well as New York and Chicago, and he now lives in Houston, Texas. Jon received a Bachelor of Business Administration in finance at University of Houston in 1992. a673b.bigscoots-temp.com.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618